Three CDK4/6i—palbociclib, ribociclib, and abemaciclib—share a common mechanism of action, inhibiting CDK4/6 to halt the phosphorylation of retinoblastoma protein and arrest the G1 cell cycle phase in tumor cells [17, 18]. The gene discussed is CDK4; the disease is neoplasm.